Patent SG-11201900132Q-A (SG)
Title: Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
Inventor: TADMOR ARBEL D
IPC: C12Q1/68
Filed: 2017-07-19
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111 0111010101111101111101 0 0111111 HE 100 11111 01H 1111E11E1111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/015433 A3 25 January 2018 (25.01.2018) WI P0 I P C T (51) International Patent Classification: GOOF 19/00 (2018.01) A61K 39/00 (2006.01) Published: C12Q 1/68 (2018.01) — with international search report (Art 21(3)) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/EP2017/068226 amendments (Rule 48.2(h)) (22) International Filing Date: — with sequence listing part of description (Rule 5.2(a)) 19 July 2017 (19.07.2017) (88) Date of publication of the international search report: 01 March 2018 (01.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/EP2016/067348 20 July 2016 (20.07.2016) EP (71) Applicant: BIONTECH RNA PHARMACEUTICALS GMBH [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE). (72) Inventors: TADMOR, Arbel D.; Am Anger 10, 55294 Bo- _ denheim (DE). SAHIN, Ugur; Philipp-von-Zabern-Platz 1, 55116 Mainz (DE). = = (74) Agent: SCHNAPPAUF, Georg; ZSP Patentanwalte PartG _ mbB, Hansastrasse 32, 80686 Mfinchen (DE). = Designated States (unless otherwise indicated, for every (81) = kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, _= = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, = = = TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. _ Designated States (unless otherwise indicated, for every — (84) _ _ kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = under Rule 4.17: en Declarations ..! — as to the applicant's entitlement to claim the priority of the M earlier application (Rule 4.17(iii)) M 71' ir) Il © (54) Title: SELECTING NEOEPITOPES AS DISEASE-SPECIFIC TARGETS FOR THERAPY WITH ENHANCED EFFICACY --.... ,-1 (57) : The present invention relates to methods for determining whether neoepitopes that are only expressed in or on diseased 0 cells arc suitable disease-specific targets, such that the diseased cell is less likely to be able to escape immune surveillance, and use of \" the neoepitopes in providing an immune response against diseased cells expressing the neoepitopes.